The extrapancreatic effects of glucagon-like peptide-1 and related peptides

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 6, 2009, Pages 1843-1852

  Abu Hamdah, Rania ^a   Rabiee, Atoosa ^a   Meneilly, Graydon S ^c   Shannon, Richard P ^d   Andersen, Dana K ^a,b   Elahi, Dariush ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CASPASE 3; DECAPENTAPLEGIC PROTEIN; DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCAGON LIKE PEPTIDE 1M; GLUCOSE; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; INSULIN RECEPTOR; LIRAGLUTIDE; METHYLTESTOSTERONE; PEPTIDE YY [3-36]; PHENTOLAMINE; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; RESERPINE; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT;

AGONIST; APPETITE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM FUNCTION; CHRONOTROPISM; CONGESTIVE CARDIOMYOPATHY; DIABETES MELLITUS; DRUG HALF LIFE; DRUG MECHANISM; FATTY LIVER; FOOD INTAKE; GASTROINTESTINAL TRACT FUNCTION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HEART FUNCTION; HEART PROTECTION; HORMONE INHIBITION; HUMAN; INOTROPISM; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SENSITIVITY; LIVER; LIVER FUNCTION; METABOLITE; NERVE CELL STIMULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS SECRETION; PRIORITY JOURNAL; REGULATORY MECHANISM; REPTILE; REVIEW; SALIVARY GLAND; SATIETY; SENSORY NERVE; SENSORY NERVE CELL; STOMACH ACID SECRETION; STOMACH EMPTYING; ANIMAL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; CHEMISTRY; DRUG EFFECT; GASTROINTESTINAL TRACT; METABOLISM; PANCREAS; PHYSIOLOGY;

HELODERMA SUSPECTUM; HELODERMATIDAE; MAMMALIA; REPTILIA;

ANIMALS; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MODELS, BIOLOGICAL; PANCREAS; PEPTIDE FRAGMENTS;

EID: 66749102158     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1296     Document Type: Review

References (118)

1. Frezza EE, Wachtel MS, Chiriva-Internati M 2007 The multiple faces of glucagon-like peptide-1-obesity, appetite, and stress: what is next? A review. Dig Dis Sci 52:643-649 (Pubitemid 46303044)
2. Bell GI, Santerre RF, Mullenbach GT 1983 Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-718
3. Lopez LC, Frazier ML, Su CJ, Kumar A, Saunders GF 1983 Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc Natl Acad Sci USA 80:5485-5489 (Pubitemid 14242873)
4. Heinrich G, Gros P, Lund PK, Bentley RC, Habener JF 1984 Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid. Endocrinology 115:2176-2181 (Pubitemid 15186251)
5. Mojsov S, Weir GC, Habener JF 1987 Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-619
6. Lund PK 2005 The discovery of glucagon-like peptide 1. Regul Pept 128:93-96 (Pubitemid 40380909)
7. Habener JF 1993 The incretin notion and its relevance to diabetes. Endocrinol Metab Clin North Am 22:775-794 (Pubitemid 24017272)
8. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, Greig NH 2002 A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300:958-966 (Pubitemid 34165002)
9. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C 2004 Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 89:3055-3061 (Pubitemid 38766408)
10. Deacon CF, Johnsen AH, Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957
11. Kieffer TJ, McIntosh CH, Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596
12. Drucker DJ, Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705 (Pubitemid 46048557)
13. Green BD, Gault VA, O'harte FP, Flatt PR 2004 Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 10:3651-3662
14. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP 1992 Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402-7405
15. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR 2001 Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161 (Pubitemid 32911763)
16. Ding X, Saxena NK, Lin S, Gupta NA, Gupta N, Anania FA 2006 Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43:173-181 (Pubitemid 43733604)
17. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD 2003 Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089 (Pubitemid 36877476)
18. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B 1992 Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283-291
19. Irwin DM 2001 Molecular evolution of proglucagon. Regul Pept 98:1-12 (Pubitemid 32155486)
20. Estall JL, Drucker DJ 2006 Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 12:1731-1750
21. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh C, Elahi D, Egan JM 1997 Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 99:2883-2889 (Pubitemid 27278664)
22. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R 2003 Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144:5149-5158 (Pubitemid 37476040)
23. List JF, Habener JF 2004 Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells. Am J Physiol Endocrinol Metab 286:E875-E881 (Pubitemid 38668807)
24. Drucker DJ 2001 Minireview: the glucagon-like peptides. Endocrinology 142:521-527 (Pubitemid 32222398)
25. Buteau J, Roduit R, Susini S, Prentki M 1999 Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in β (INS-1)-cells. Diabetologia 42:856-864 (Pubitemid 29325077)
26. Ahrén B 2004 GLP-1 and extra-islet effects. Horm Metab Res 36:842-845 (Pubitemid 40115908)
27. Valverde I, Morales M, Clemente F, López-Delgado MI, Delgado E, Perea A, Villanueva-Peñacarrillo ML 1994 Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349:313-316 (Pubitemid 24263284)
28. Villanueva-Peñacarrillo ML, Alcántara AI, Clemente F, Delgado E, Valverde I 1994 Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37:1163-1166
29. Galera C, Clemente F, Alcantara A, Trapote MA, Perea A, Lopez-Delgado MI, Villanueva-Penacarrillo ML, Valverde I 1996 Inositolphosphoglycans and diacyglycerol are possible mediators in the glycogenic effect of GLP-1(7-36)amide in BC3H-1 myocytes. Cell Biochem Funct 14:43-48
30. Wheeler MB, Lu M, Dillon JS, Leng XH, Chen C, Boyd 3rd AE 1993 Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 133:57-62 (Pubitemid 23206374)
31. Holst JJ 2007 The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439 (Pubitemid 350041474)
32. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD 2004 Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab 287:E75-E81 (Pubitemid 38856285)
33. Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF, Andersen DK 2008 GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity 16:1501-1509
34. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP 2004 Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962-965 (Pubitemid 38282847)
35. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH 1997 Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988 (Pubitemid 27505833)
36. Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Göke B, Katschinski M 1997 Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 109:84-97 (Pubitemid 27161053)
37. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B 2006 Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55:243-251 (Pubitemid 43117285)
38. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S, Hellström PM1999 Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304-311
39. Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A 2001 The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25:781-792 (Pubitemid 32601369)
40. Meier S, Hücking K, Ritzel R, Holst JJ, Schmiegel WH, Nauck MA 2003 Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers. Horm Metab Res 35:551-556 (Pubitemid 37260421)
41. Silvestre RA, Rodríguez-Gallardo J, Egido EM, Marco J 2003 Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. Eur J Pharmacol 469:195-200 (Pubitemid 36629566)
42. Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, Schuit FC 2001 Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 438:382-387 (Pubitemid 32285364)
43. Nagai K, Tsuchiya K, Ezaki T, Tsuchiya M, Ohgawara H 2004 Effect of GLP-1 (glucagon-like peptide 1:7-36 amide) on porcine pancreatic endocrine cell proliferation and insulin secretion. Pancreas 28:138-145 (Pubitemid 38269773)
44. D'Alessio D 2008 Intestinal hormones and regulation of satiety: the case for CCK, GLP-1, PYY, and Apo A-IV. JPEN J Parenter Enteral Nutr 32:567-568
45. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165 (Pubitemid 43316521)
46. Vrang N, Phifer CB, Corkern MM, Berthoud HR 2003 Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. Am J Physiol Regul Integr Comp Physiol 285:R470-R478 (Pubitemid 36898916)
47. Kinzig KP, D'Alessio DA, Seeley RJ 2002 The diverse roles of specific GLP-1Rs in the control of food intake and the response to visceral illness. J Neurosci 22:10470-10476 (Pubitemid 35416883)
48. Larsen PJ, Tang-Christensen M, Jessop DS 1997 Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 138:4445-4455 (Pubitemid 27408493)
49. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR 2004 Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687-2695 (Pubitemid 38686215)
50. Imeryüz N, Yeoen BC, Bozkurt A, Copkun T, Villanueva- Peñacarrillo ML, Ulusoy NB 1997 Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273:G920-G927 (Pubitemid 27473676)
51. Kakei M, Yada T, Nakagawa A, Nakabayashi H 2002 Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons. Auton Neurosci 102:39-44 (Pubitemid 35305005)
52. Baggio LL, Huang Q, Brown TJ, Drucker DJ 2004 A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1R-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53:2492-2500 (Pubitemid 39145610)
53. Meier JJ, Kemmeries G, Holst JJ, Nauck MA 2005 Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54:2212-2218 (Pubitemid 40911286)
54. Schmidtler J, Dehne K, Allescher HD, Schusdziarra V, Classen M, Holst JJ, Polack A, Schepp W 1994 Rat parietal cell receptors for GLP-1-(7-36) amide: Northern blot, cross-linking, and radioligand binding. Am J Physiol 267:G423-G432
55. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ 1997 The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40:597-601 (Pubitemid 27278325)
56. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M 2002 Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 282:G424-G431 (Pubitemid 34651657)
57. Schirra J, Katschinski M, Weidmann C, Schäfer T, Wank U, Arnold R, Göke B 1996 Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97:92-103 (Pubitemid 26021698)
58. D'Alessio DA, Vogel R, Prigeon R, Laschansky E, Koerker D, Eng J, Ensinck JW 1996 Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138 (Pubitemid 26021703)
59. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Camilleri M 2007 Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56:1475-1480 (Pubitemid 46715627)
60. Salehi M, Vahl TP, D'Alessio DA 2008 Regulation of islet hormone release and gastric emptying by endogenous GLP-1 following glucose ingestion. J Clin Endocrinol Metab 93:4909-4916
61. Elahi D, Nagulesparan M, Hershcopf RJ, Muller DC, Tobin JD, Blix PM, Rubenstein AH, Unger RH, Andres R 1982 Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity. N Engl J Med 306:1196-1202
62. Bullock BP, Heller RS, Habener JF 1996 Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137:2968-2978 (Pubitemid 26192194)
63. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M 2008 Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340-2350
64. Barragán JM, Rodríguez RE, Blázquez E 1994 Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 266:E459-E466 (Pubitemid 24115802)
65. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK 2002 Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43-52 (Pubitemid 34743464)
66. Barragán JM, Eng J, Rodríguez R, Blázquez E 1999 Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 277:E784-E791
67. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, Stolarski C, Shen YT, Shannon RP 2004 Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955-961 (Pubitemid 39128621)
68. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP 2006 Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12:694-699 (Pubitemid 44881367)
69. Bose AK, Mocanu MM, Carr RD, Yellon DM 2005 Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther 19:9-11 (Pubitemid 40767767)
70. Nikolaidis LA, Doverspike A, Hentosz T, Zourelias L, Shen YT, Elahi D, Shannon RP 2005 Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 312:303-308 (Pubitemid 40096482)
71. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, Shannon RP 2006 Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317:1106-1113 (Pubitemid 43764114)
72. Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern Jr GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP 2007 Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100:824-829 (Pubitemid 47268274)
73. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO 2001 Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 102:81-86
74. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM 2005 Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54:146-151 (Pubitemid 40105106)
75. Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, Drucker DJ 2003 International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55:167-194
76. Thorens B 1992 Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89:8641-8645
77. Nikolaidis LA, Elahi D, Shen YT, Shannon RP 2005 Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289:H2401-H2408 (Pubitemid 41698549)
78. Brunner F, Maier R, Andrew P, Wölkart G, Zechner R, Mayer B 2003 Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc Res 57:55-62 (Pubitemid 36009436)
79. Poornima IB, Bhashyam S, Parikh P, Bolukoglu H, Shannon R 2008 Chronic glucagon-like peptide-1 infusion sustains left ventricular function and prolongs survival in spontaneously hypertensive, heart failure prone rats. Circ Heart Fail 1:153-160
80. D'Alessio D, Vahl T, Prigeon R 2004 Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. Horm Metab Res 36:837-841 (Pubitemid 40115907)
81. Alcántara AI, Morales M, Delgado E, López-Delgado MI, Clemente F, Luque MA, Malaisse WJ, Valverde I, Villanueva-Peñacarrillo ML 1997 Exendin-4 agonist and exendin (9-39) amide antagonist of the GLP-1 (7-36) amide effects in liver and muscle. Arch Biochem Biophys 341:1-7
82. López-Delgado MI, Morales M, Villanueva-Peñacarrillo ML, Malaisse WJ, Valverde I 1998 Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase A in hepatocytes from normal and diabetic rats. Endocrinology 139:2811-2817 (Pubitemid 28512390)
83. Nathan JD, Zdankiewicz PD, Wang J, Spector SA, Aspelund G, Jena BP, Seymour NE, Geibel JP, Andersen DK 2001 Impaired hepatocyte glucose transport protein (GLUT2) internalization in chronic pancreatitis. Pancreas 22:172-178 (Pubitemid 32179172)
84. Andersen DK, Ruiz CL, Burant CF 1994 Insulin regulation of hepatic glucose transporter protein is impaired in chronic pancreatitis. Ann Surg 219:679-686; discussion, 686-1677 (Pubitemid 24182642)
85. Eisenberg ML, Maker AV, Slezak LA, Nathan JD, Sritharan KC, Jena BP, Geibel JP, Andersen DK 2005 Insulin receptor (IR) and glucose transporter 2 (GLUT2) proteins form a complex on the rat hepatocyte membrane. Cell Physiol Biochem 15:51-58
86. Brunicardi FC, Chaiken RL, Ryan AS, Seymour NE, Hoffmann JA, Lebovitz HE, Chance RE, Gingerich RL, Andersen DK, Elahi D 1996 Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab 81:3566-3572 (Pubitemid 26339916)
87. Andersen DK 2007 Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis. Pancreas 35:1-15 (Pubitemid 46956195)
88. Egan JM, Meneilly GS, Habener JF, Elahi D 2002 Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87:3768-3773 (Pubitemid 34879525)
89. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA 2003 Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88:1772-1779
90. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ 1995 Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126-1131
91. Campos RV, Lee YC, Drucker DJ 1994 Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134:2156-2164 (Pubitemid 24142957)
92. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, Giacca A 1999 Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 48:1045-1053 (Pubitemid 29226351)
93. Zander M, Madsbad S, Deacon CF, Holst JJ 2006 The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia 49:369-374 (Pubitemid 43185406)
94. Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK 1988 Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519-532 (Pubitemid 18136064)
95. Van Dijk G, Thiele TE, Donahey JC, Campfield LA, Smith FJ, Burn P, Bernstein IL, Woods SC, Seeley RJ 1996 Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain. Am J Physiol 271:R1096-R1100
96. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR 1996 A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72 (Pubitemid 26008136)
97. Nakade Y, Tsukamoto K, Pappas TN, Takahashi T 2006 Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res 1111:117-121 (Pubitemid 44331186)
98. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, Uchida K 2000 The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1R. J Auton Nerv Syst 80:14-21 (Pubitemid 30160722)
99. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh SP 1996 Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856
100. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA, Bloom SR 1999 Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244-250
101. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR 2002 Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654
102. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR 2003 Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941-948 (Pubitemid 37064767)
103. Beak SA, Small CJ, Ilovaiskaia I, Hurley JD, Ghatei MA, Bloom SR, Smith DM1996 Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on α-TSH cells. Endocrinology 137:4130-4138 (Pubitemid 26321857)
104. Beak SA, Heath MM, Small CJ, Morgan DG, Ghatei MA, Taylor AD, Buckingham JC, Bloom SR, Smith DM 1998 Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. J Clin Invest 101:1334-1341 (Pubitemid 28145250)
105. Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, D'Alessio D 2000 The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 20:1616-1621
106. Jang HJ, Kokrashvili Z, Theodorakis MJ, Carlson OD, Kim BJ, Zhou J, Kim HH, Xu X, Chan SL, Juhaszova M, Bernier M, Mosinger B, Margolskee RF, Egan JM 2007 Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci USA 104:15069-15074 (Pubitemid 47619594)
107. Shin YK, Martin B, Golden E, Dotson CD, Maudsley S, Kim W, Jang HJ, Mattson MP, Drucker DJ, Egan JM, Munger SD 2008 Modulation of taste sensitivity by GLP-1 signaling. J Neurochem 106:455-463
108. Egan JM, Margolskee RF 2008 Taste cells of the gut and gastrointestinal chemosensation. Mol Interv 8:78-81
109. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, Egan JM 2000 Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141:1936-1941 (Pubitemid 32274340)
110. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M1999 Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034
111. Schnabel CA, Wintle M, Kolterman O 2006 Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag 2:69-77
112. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
113. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830 (Pubitemid 34233752)
114. Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D 2003 Effects of 3 months of continuous subcutaneous administration of glucagonlike peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 26:2835-2841 (Pubitemid 37205555)
115. Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani-Guglielmacci C, Pénicaud L, Drucker DJ, Magnan C, Burcelin R 2008 Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57:2577-2587
116. Nyström T, Gonon AT, Sjöholm A, Pernow J 2005 Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 125:173-177 (Pubitemid 39593722)
117. Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ 2007 Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 293:E1289-E1295 (Pubitemid 350106596)
118. Saraceni C, Broderick TL 2007 Effects of glucagon-like peptide-1 and longacting analogues on cardiovascular and metabolic function. Drugs R D 8:145-153 (Pubitemid 46707838)